Inhibrx Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INBX research report →
Range $325 – $325
Price Chart
About the company
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function.
- CEO
- Mark Lappe
- IPO
- 2024
- Employees
- 110
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on INBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.45B
- P/E
- -11.17
- Fwd P/E
- 36.65
- PEG
- -0.60
- P/S
- 0.00
- P/B
- -29.33
- EV/EBITDA
- -11.01
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1893.60%
- ROIC
- -99.35%
Latest fiscal year · YoY change
- Revenue
- $1.30M+550.0%
- Gross Profit
- $-1,183,000+43.3%
- Op Income
- $-135,025,000
- Net Income
- $-140,055,000-108.3%
- EPS
- $-9.04-107.8%
- OCF Growth
- +33.2%
- FCF Growth
- +34.1%
- 52W High
- $155.29
- 52W Low
- $23.77
- 50D MA
- $91.03
- 200D MA
- $86.60
- Beta
- 3.52
- RSI (14)
- 59
- Avg Volume
- 299.66K
No earnings-call transcripts are available for INBX yet.
- Free Float
- 74.1%
- Shares Outstanding
- 14.67M
- Float Shares
- 10.87M
of shares held by institutions
147 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 1.31M | ▲ 44.97K |
| Perceptive Advisors LLC | 1.30M | ▼ 144.94K |
| Sanofi | 1.16M | 0 |
| Viking Global Investors LP | 1.12M | ▼ 313.78K |
| Hightower Advisors, LLC | 870.55K | ▲ 351 |
| Bank Of America Corp | 841.14K | ▲ 808.46K |
| Blackrock, Inc. | 825.97K | ▲ 27.07K |
| Schonfeld Strategic Advisors LLC | 697.59K | ▲ 442.76K |
| State Street Corp | 640.46K | ▲ 89.61K |
| Vanguard Group Inc | 623.08K | ▲ 28.17K |
| Vanguard Capital Management LLC | 492.48K | ▲ 6.05K |
| Woodline Partners LP | 400.89K | ▲ 16.46K |
Held by 171 ETFs
Biggest fund positions in INBX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 3, 26 | Vuori Kristiina MD | other | 15,000 |
| Jun 3, 26 | Kayyem Jon Faiz | other | 15,000 |
| Jun 3, 26 | FORSYTH DOUGLAS | other | 15,000 |
| Jun 3, 26 | MANHARD KIMBERLY | other | 15,000 |
| Apr 24, 26 | Matly David | other | 50,000 |
| Oct 7, 25 | VIKING GLOBAL INVESTORS LP | sell | 308,643 |
| Oct 7, 25 | VIKING GLOBAL INVESTORS LP | sell | 25,042 |
| Oct 7, 25 | VIKING GLOBAL INVESTORS LP | sell | 16,315 |
| May 28, 25 | MANHARD KIMBERLY | other | 15,000 |
| May 28, 25 | Vuori Kristiina MD | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INBX coverage
Recent articles, reports, and earnings notes.
No research on INBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INBX report →Inhibrx Reports Second Quarter 2026 Financial Results
prnewswire.com · Aug 13
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
seekingalpha.com · Jul 17
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
prnewswire.com · Jul 16
Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice
zacks.com · Jul 9
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
prnewswire.com · Jun 15
Inhibrx Reports First Quarter 2026 Financial Results
prnewswire.com · May 14
Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study
benzinga.com · May 11
Inhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study
marketbeat.com · May 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.